MK-677, also known as Ibutamoren, is a non-peptide growth hormone secretagogue and a selective agonist of the ghrelin receptor primarily used to stimulate the release of growth hormone and insulin-like growth factor (IGF-1) in the body. It is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone-stimulating action of the endogenous hormone ghrelin. MK-677 has been shown to improve growth hormone levels in children with growth hormone deficiency. It has also been used experimentally by some in the bodybuilding community. MK-677 has been found to reverse diet-induced nitrogen wasting, suggesting that it may be useful in treating catabolic conditions. It has been shown to be generally well-tolerated and without clinically significant adverse experiences. Since MK-677 is still an Investigational New Drug, it has not yet been approved to be marketed for consumption by humans in the United States. The recommended dosage of MK-677 varies depending on the individual case, ranging from 2 mg to 50 mg, although 25 mg is the most commonly suggested dose recommended by most doctors and researchers as a treatment for growth hormone deficiency.